Evidence map›Paper›PMID 35734082›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Overt and occult hypoxemia in patients hospitalized with novel coronavirus disease 2019.

Shrirang M Gadrey, Piyus Mohanty, Sean P Haughey, Beck A Jacobsen, Kira J Dubester, Katherine M Webb, Rebecca L Kowalski, Jessica J Dreicer, Robert T Andris, Matthew T Clark and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Shrirang M GadreyUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Piyus MohantyUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Sean P HaugheyUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Beck A JacobsenUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Kira J DubesterUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Katherine M WebbUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Rebecca L KowalskiUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Jessica J DreicerUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Robert T AndrisUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Matthew T ClarkUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Christopher C MooreUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Andre HolderUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Rishi KamaleswaranUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Sarah J RatcliffeUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
J Randall MoormanUniversity of Virginia School of Medicine, Charlottesville; and Emory University, Atlanta, USA.
Emory University · US

Funding

A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan AfricaU01AI150508 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, MOORE, CHRISTOPHER CHARLES · 2020 to 2024
$3.3M
Sepsis Physiomarkers for Appropriate Risk Knowledge of monitored patients in the ICU (SPARK-ICU)R01GM139967 · NIGMS · EMORY UNIVERSITY · PI KAMALESWARAN, RISHIKESAN · 2021 to 2025
$2.8M
Characterizing patients at risk for sepsis through Big Data (Supplement)K23GM137182 · NIGMS · EMORY UNIVERSITY · PI HOLDER, ANDRE L · 2020 to 2023
$907k
NIAID NIH HHS U01 AI150508NIGMS NIH HHS K23 GM137182NIGMS NIH HHS R01 GM139967
6 · The paper itself

Abstract

Background: Progressive hypoxemia is the predominant mode of deterioration in COVID-19. Among hypoxemia measures, the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (P/F ratio) has optimal construct validity but poor availability because it requires arterial blood sampling. Pulse oximetry reports oxygenation continuously, but occult hypoxemia can occur in Black patients because the technique is affected by skin color. Oxygen dissociation curves allow non-invasive estimation of P/F ratios (ePFR) but this approach remains unproven. Research Question: Can ePFRs measure overt and occult hypoxemia? Study Design and methods: We retrospectively studied COVID-19 hospital encounters (n=5319) at two academic centers (University of Virginia [UVA] and Emory University). We measured primary outcomes (death or ICU transfer within 24 hours), ePFR, conventional hypoxemia measures, baseline predictors (age, sex, race, comorbidity), and acute predictors (National Early Warning Score (NEWS) and Sepsis-3). We updated predictors every 15 minutes. We assessed predictive validity using adjusted odds ratios (AOR) and area under receiver operating characteristics curves (AUROC). We quantified disparities (Black vs non-Black) in empirical cumulative distributions using the Kolmogorov-Smirnov (K-S) two-sample test. Results: Overt hypoxemia (low ePFR) predicted bad outcomes (AOR for a 100-point ePFR drop: 2.7 [UVA]; 1.7 [Emory]; p<0.01) with better discrimination (AUROC: 0.76 [UVA]; 0.71 [Emory]) than NEWS (AUROC: 0.70 [UVA]; 0.70 [Emory]) or Sepsis-3 (AUROC: 0.68 [UVA]; 0.65 [Emory]). We found racial differences consistent with occult hypoxemia. Black patients had better apparent oxygenation (K-S distance: 0.17 [both sites]; p<0.01) but, for comparable ePFRs, worse outcomes than other patients (AOR: 2.2 [UVA]; 1.2 [Emory], p<0.01). Interpretation: The ePFR was a valid measure of overt hypoxemia. In COVID-19, it may outperform multi-organ dysfunction models like NEWS and Sepsis-3. By accounting for biased oximetry as well as clinicians’ real-time responses to it (supplemental oxygen adjustment), ePFRs may enable statistical modelling of racial disparities in outcomes attributable to occult hypoxemia.

Identifiers

PMID35734082
PMCPMC9216725
OpenAlexW4283023038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.